GeneHealth - Your precision medicine

Hereditary Hemorrhagic Telangiectasia

Disease Details

Family Health Simplified

Buy Membership

Description: Hereditary hemorrhagic telangiectasia is a genetic disorder that causes abnormal blood vessel formation leading to bleeding in various organs.
Type: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder.
Signs And Symptoms: Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a genetic disorder affecting blood vessels.

**Signs and Symptoms:**
1. **Nosebleeds (Epistaxis):** Frequent and recurrent nosebleeds are one of the most common signs.
2. **Telangiectasias:** Small, red or purple spots on the skin and mucous membranes, including the face, lips, mouth, and fingers.
3. **Arteriovenous Malformations (AVMs):** Abnormal connections between arteries and veins that can occur in organs such as the lungs, liver, brain, and gastrointestinal tract.
4. **Gastrointestinal Bleeding:** Telangiectasias in the digestive tract can cause chronic bleeding, leading to anemia.
5. **Anemia:** Due to chronic blood loss from recurrent nosebleeds or gastrointestinal bleeding.
6. **Pulmonary Symptoms:** Shortness of breath or exercise intolerance can result from pulmonary AVMs.
7. **Neurological Symptoms:** AVMs in the brain can cause headaches, seizures, or more serious complications like strokes.

It is important to note that the severity and combination of symptoms can vary widely among individuals.
Prognosis: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by abnormal blood vessel formation. The prognosis for individuals with HHT varies depending on the severity and complications of the disease. Many people live a normal lifespan with proper management of symptoms, which typically includes controlling nosebleeds, treating anemia, and monitoring for complications such as arteriovenous malformations (AVMs) in the lungs, liver, and brain. Early detection and treatment of these complications are crucial to prevent serious health issues. Regular follow-up with healthcare providers experienced in HHT is recommended to manage the condition effectively.
Onset: Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, can have an onset at any age, but most commonly presents in adolescence or early adulthood. The first symptom often noticed is recurrent nosebleeds (epistaxis).
Prevalence: The prevalence of hereditary hemorrhagic telangiectasia (HHT) is estimated to be approximately 1 in 5,000 to 8,000 individuals worldwide.
Epidemiology: Population studies from numerous areas in the world have shown that HHT occurs at roughly the same rate in almost all populations: somewhere around 1 in 5000. In some areas, it is much more common; for instance, in the French region of Haut Jura the rate is 1:2351
Intractability: Hereditary hemorrhagic telangiectasia (HHT) is not considered intractable, but it is a chronic condition that requires ongoing management. There is no cure, but various treatments can help control symptoms and reduce complications, which may include nosebleeds, gastrointestinal bleeding, and arteriovenous malformations. Management typically involves addressing specific symptoms and complications through medical, surgical, or interventional procedures.
Disease Severity: Hereditary hemorrhagic telangiectasia (HHT) disease severity can vary widely among individuals. Some people may experience mild symptoms such as occasional nosebleeds, while others might face more severe complications involving arteriovenous malformations (AVMs) in organs such as the lungs, liver, and brain. Severe cases can lead to significant health issues, including bleeding in critical areas, organ failure, or stroke. Regular monitoring and management are essential to address the potential complications associated with this genetic disorder.
Healthcare Professionals: Disease Ontology ID - DOID:1270
Pathophysiology: Telangiectasias and arteriovenous malformations in HHT are thought to arise because of changes in angiogenesis, the development of blood vessels out of existing ones. The development of a new blood vessel requires the activation and migration of various types of cells, chiefly endothelium, smooth muscle and pericytes. The exact mechanism by which the HHT mutations influence this process is not yet clear, and it is likely that they disrupt a balance between pro- and antiangiogenic signals in blood vessels. The wall of telangiectasias is unusually friable, which explains the tendency of these lesions to bleed.All genes known so far to be linked to HHT code for proteins in the TGF-β signaling pathway. This is a group of proteins that participates in signal transduction of hormones of the transforming growth factor beta superfamily (the transforming growth factor beta, bone morphogenetic protein and growth differentiation factor classes), specifically BMP9/GDF2 and BMP10. The hormones do not enter the cell but link to receptors on the cell membrane; these then activate other proteins, eventually influencing cellular behavior in a number of ways such as cellular survival, proliferation (increasing in number) and differentiation (becoming more specialized). For the hormone signal to be adequately transduced, a combination of proteins is needed: two each of two types of serine/threonine-specific kinase type membrane receptors and endoglin. When bound to the hormone, the type II receptor proteins phosphorylate (transfer phosphate) onto type I receptor proteins (of which Alk-1 is one), which in turn phosphorylate a complex of SMAD proteins (chiefly SMAD1, SMAD5 and SMAD8). These bind to SMAD4 and migrate to the cell nucleus where they act as transcription factors and participate in the transcription of particular genes. In addition to the SMAD pathway, the membrane receptors also act on the MAPK pathway, which has additional actions on the behavior of cells. Both Alk-1 and endoglin are expressed predominantly in endothelium, perhaps explaining why HHT-causing mutations in these proteins lead predominantly to blood vessel problems. Both ENG and ACVRL1 mutations lead predominantly to underproduction of the related proteins, rather than misfunctioning of the proteins.
Carrier Status: For Hereditary Hemorrhagic Telangiectasia (HHT), carrier status is not typically applicable as it is an autosomal dominant condition. This means that only one copy of the mutated gene from an affected parent is sufficient to cause the disorder. Individuals cannot be "carriers" in the traditional sense (like in autosomal recessive conditions) because they will usually manifest symptoms if they inherit the mutated gene.
Mechanism: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that affects blood vessels. The primary mechanism involves the development of abnormal blood vessels called telangiectasias and arteriovenous malformations (AVMs) that can lead to bleeding and related complications.

**Molecular Mechanisms:**
1. **Genetic Mutations**: HHT is most commonly caused by mutations in several genes. The two most affected genes are ENDOGLIN (ENG) and ACVRL1 (also known as ALK1). Mutations in these genes disrupt the normal function of proteins involved in blood vessel formation and repair.

2. **ENG (Endoglin)**: This protein is an accessory receptor for transforming growth factor-beta (TGF-β), which plays a crucial role in vascular development and integrity. Mutations in ENG lead to impaired signaling pathways necessary for blood vessel stabilization and repair, resulting in fragile and abnormal vessels.

3. **ACVRL1 (ALK1)**: This is a receptor serine/threonine kinase, also part of the TGF-β signaling pathway, specifically involved in vascular endothelial function. Mutations in ACVRL1 interfere with endothelial cell communication and vessel maturation, contributing to the formation of telangiectasias and AVMs.

4. **SMAD4 (Less Common)**: Mutations in the SMAD4 gene, involved in the downstream signaling of TGF-β pathways, can also lead to a combined syndrome of HHT and juvenile polyposis, further complicating vessel integrity and function.

5. **Pathway Disruption**: The mutations disrupt the TGF-β/BMP signaling pathways, leading to altered endothelial cell behavior, increased vascular permeability, and the formation of malformed blood vessels prone to rupture and bleeding.

These genetic and molecular disruptions collectively lead to the clinical manifestations observed in HHT, including recurrent epistaxis (nosebleeds), mucocutaneous telangiectasias, and AVMs in organs like the lungs, liver, and brain.
Treatment: Treatment of HHT is symptomatic (it deals with the symptoms rather than the disease itself), as there is no therapy that stops the development of telangiectasias and AVMs directly. Furthermore, some treatments are applied to prevent the development of common complications. Chronic nosebleeds and digestive tract bleeding can both lead to anemia; if the bleeding itself cannot be completely stopped, the anemia requires treatment with iron supplements. Those who cannot tolerate iron tablets or solutions may require administration of intravenous iron, and blood transfusion if the anemia is causing severe symptoms that warrant rapid improvement of the blood count.Most treatments used in HHT have been described in adults, and the experience in treating children is more limited. Women with HHT who get pregnant are at an increased risk of complications, and are observed closely, although the absolute risk is still low (1%).
Compassionate Use Treatment: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that affects blood vessels. Currently, there are no FDA-approved treatments specifically for HHT, but several off-label and experimental treatments are being explored.

1. **Bevacizumab**: Originally an anti-cancer drug, this medication has been used off-label to manage severe bleeding in HHT patients by inhibiting blood vessel formation.

2. **Thalidomide and Lenalidomide**: These immunomodulatory drugs are being studied for their potential to reduce bleeding episodes and improve anemia associated with HHT.

3. **Anti-fibrinolytics**: Medications such as tranexamic acid are sometimes used off-label to reduce bleeding by stabilizing blood clots.

4. **Sirolimus**: This drug is being investigated for its potential to manage symptoms of HHT by inhibiting pathways that contribute to abnormal blood vessel formation.

Compassionate use might be considered for these treatments if standard management strategies are not effective and the patient's condition is severe. It's important to consult with a healthcare provider who specializes in HHT for personalized advice and potential access to experimental therapies or participation in clinical trials.
Lifestyle Recommendations: For individuals with hereditary hemorrhagic telangiectasia (HHT), certain lifestyle recommendations can help manage symptoms and reduce complications:

1. **Avoid Trauma**: Minimize activities that can lead to injury, especially to the nose and mouth, to prevent bleeding.
2. **Nasal Care**: Keep nasal passages moist using saline sprays or humidifiers to reduce nosebleeds.
3. **Good Oral Hygiene**: Regular dental check-ups and gentle oral care can help prevent gum and nose bleeds.
4. **Avoid Blood Thinners**: Unless prescribed, avoid medications like aspirin and ibuprofen that can increase bleeding risks.
5. **Diet and Hydration**: Maintain a healthy diet rich in iron to counteract blood loss from bleeding. Stay well-hydrated.
6. **Avoid High Altitudes**: High altitudes may exacerbate nosebleeds due to dry air and lower oxygen levels.
7. **Regular Monitoring**: Regular check-ups with specialized healthcare providers for monitoring and managing potential complications such as anemia, arteriovenous malformations (AVMs), and gastrointestinal bleeding.
8. **Exercise Caution**: Engage in regular, moderate exercise but avoid heavy lifting or strenuous activities that might trigger bleeding.

Following these recommendations can help manage symptoms and improve the quality of life for those with HHT.
Medication: Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a genetic disorder that leads to abnormal blood vessel formation. Medication for HHT is primarily aimed at managing symptoms and preventing complications, rather than curing the disease. Common medications might include:

1. **Anti-angiogenic Agents**: Drugs such as bevacizumab, which can reduce bleeding by inhibiting the formation of new blood vessels.
2. **Hormonal Therapy**: Medications like estrogen-progestin can help decrease the frequency of nosebleeds and gastrointestinal bleeding.
3. **Antibiotics**: For patients with pulmonary arteriovenous malformations (AVMs), prophylactic antibiotics are sometimes used during dental procedures to prevent infections that could lead to brain abscesses.

Other treatments may include laser therapy and surgical interventions depending on the severity and location of the arteriovenous malformations or telangiectasias. Regular follow-up with healthcare professionals is essential for monitoring and managing the condition.
Repurposable Drugs: Hereditary hemorrhagic telangiectasia (HHT) currently lacks FDA-approved treatments specifically targeting the disease. However, several drugs approved for other conditions show potential for repurposing in HHT. These include:

1. **Bevacizumab (Avastin)**: An anti-VEGF monoclonal antibody that has shown effectiveness in reducing nosebleeds and gastrointestinal bleeding in HHT patients.

2. **Thalidomide** and related **IMiDs (Immunomodulatory Drugs)**: These can potentially decrease bleeding complications by promoting endothelial stability and reducing new blood vessel formation.

3. **Propranolol**: A beta-blocker that has shown promise in reducing the frequency and severity of nosebleeds, potentially by reducing blood flow to affected areas.

These drugs are under various stages of investigation, and their use in HHT should be guided by a healthcare professional.
Metabolites: For hereditary hemorrhagic telangiectasia (HHT), no specific metabolites are diagnostically associated with the disease. HHT is primarily a genetic disorder involving vascular malformations. Diagnosis and management focus on clinical evaluation, genetic testing, and imaging studies rather than metabolic profiling.
Nutraceuticals: Hereditary hemorrhagic telangiectasia (HHT) management primarily focuses on treating symptoms and preventing complications. Nutraceuticals, which include food-derived products and supplements, do not have a well-established role in the treatment or management of HHT. Instead, treatment typically involves medical and surgical approaches to control bleeding, prevent anemia, and manage vascular malformations. Regular medical follow-up is essential. Always consult a healthcare professional for personalized advice and treatment options.
Peptides: Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder characterized by abnormal blood vessel formation. Regarding peptides, research is being conducted to explore their potential in targeting vascular anomalies associated with HHT, but specific therapeutic peptides are not currently standard treatment. Nanotechnology applications (nan) are also being researched for their potential to deliver drugs more effectively to affected blood vessels, though this is still largely in experimental stages.